Sputum interleukin-6 level as a marker of severity during acute chest syndrome in children with sickle cell disease.
Lara MayrandJuliette ElieYael PinhasRachel Rignault-BricardMelissa TaylorJoséphine BriceMariane de MontalembertClaire HeilbronnerAgathe BerangerSofia AngyalosyStephanie ChhunThiago Trovati MacielOlivier HermineSlimane AllaliPublished in: British journal of haematology (2024)
Acute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin-6 (IL-6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL-6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non-invasive) length ≥5 days, bilateral and/or extensive opacities on chest X-ray or erythrocytapheresis requirement. Sputum IL-6 could serve as an ACS severity marker to help identify patients requiring targeted anti-inflammatory treatments such as tocilizumab.
Keyphrases
- acute coronary syndrome
- cystic fibrosis
- pulmonary tuberculosis
- mycobacterium tuberculosis
- sickle cell disease
- respiratory failure
- liver failure
- end stage renal disease
- young adults
- anti inflammatory
- case report
- ejection fraction
- newly diagnosed
- chronic kidney disease
- drug induced
- aortic dissection
- peritoneal dialysis
- rheumatoid arthritis
- extracorporeal membrane oxygenation
- cancer therapy
- computed tomography
- systemic lupus erythematosus
- intensive care unit
- patient reported outcomes
- hepatitis b virus
- electron microscopy